Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy and safety of Anlotinib plus Icotinib as the first-line treatment in
patients with sensitive EGFR concomitant mutations advanced non-small cell lung cancer
Phase:
Phase 3
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital